These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
486 related items for PubMed ID: 17382713
1. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, Dalbagni G. J Urol; 2007 Apr; 177(4):1283-6; discussion 1286. PubMed ID: 17382713 [Abstract] [Full Text] [Related]
2. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798 [Abstract] [Full Text] [Related]
5. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M. J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729 [Abstract] [Full Text] [Related]
6. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. Alkhateeb SS, Van Rhijn BW, Finelli A, van der Kwast T, Evans A, Hanna S, Vajpeyi R, Fleshner NE, Jewett MA, Zlotta AR. J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593 [Abstract] [Full Text] [Related]
7. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. Herr HW. J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743 [Abstract] [Full Text] [Related]
8. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. Pansadoro V, Emiliozzi P, Defidio L, Donadio D, Florio A, Maurelli S, Lauretti S, Sternberg CN. J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457 [Abstract] [Full Text] [Related]
15. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy. Margel D, Tal R, Golan S, Kedar D, Engelstein D, Baniel J. Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621 [Abstract] [Full Text] [Related]
16. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer. Guevara A, Salomon L, Allory Y, Ploussard G, de la Taille A, Paul A, Yiou R, Hoznek A, Dahan M, Abbou CC, Vordos D. J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454 [Abstract] [Full Text] [Related]
17. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, Villavicencio H. Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115 [Abstract] [Full Text] [Related]
18. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Esrig D, Freeman JA, Stein JP, Skinner DG. Semin Urol Oncol; 1997 Aug; 15(3):154-60. PubMed ID: 9394910 [Abstract] [Full Text] [Related]
19. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA. J Urol; 2009 Nov; 182(5):2195-203. PubMed ID: 19758621 [Abstract] [Full Text] [Related]